Recce Pharmaceuticals (ASX:RCE) Secures China Patent for Anti-Infectives
China Patent Acceptance
Recce Pharmaceuticals Limited (ASX:RCE) announced the acceptance of its Family 4 patent for RECCE® 327 and RECCE® 529 by the China National Intellectual Property Administration. The patents, valid until 2041, cover processes for preparation and various therapeutic uses of the anti-infectives.
Patent Details
The China Patent includes methods for treating bacterial and viral infections, administration routes such as oral and inhalation, and delivery forms like aerosols and gels. This marks Recce’s fifth Family 4 patent, with additional patents granted in Australia, Canada, Israel, and Japan.
Market Significance
China is the world’s second-largest pharmaceutical market, with its antibiotic sector valued at approximately US$4.09 billion and expected to grow at a 5.7% CAGR from 2025 to 2030. The patent strengthens Recce’s position in this key market.
Executive Comments
Chief Executive Officer James Graham stated, “This patent will broaden our patent portfolio for Family 4 out to the second largest pharmaceutical market in the world. We thank the China National Intellectual Property Administration for their formal recognition of technical advantages of Recce’s New Class of Anti-Infectives.”
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
